Recruiting NCT06073834
LUNG INFECTION in ICU (LUNG-I3)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: VAP - Ventilator Associated Pneumonia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
LUNG INFECTION in ICU
Overview
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
Primary outcome measures
- immune cells patterns in VAP [Time frame: before and at time of VAP diagnosis]
Eligibility criteria
Inclusion criteria
All the following criteria
- Age 18 years or greater
- Severe ICU patients hospitalized for one of the above diseases:
- Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)
- Severe trauma (level I and II), Injury Severity Score ≥ 25 OR
- Burn with TBSA over 20%
- NAD > 0.1 µg/kg/min
- At least 2 SOFA criteria ≥ 2 points
Exclusion criteria
- Aspiration pneumonia
- Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
- COPD
- Smoke inhalation in burn patients
- Participation in an intervention study
- Pregnant or breastfeeding women
- Immunocompromised patients, defined as
- patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease
- hematologic malignancies
- solid organ transplantation
- HIV infection with or without AIDS
- treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day)
- treatment with other immunosuppressive drugs.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
France · 1 center
- Hopital Edouard Herriot — Lyon
Identifiers
NCT: NCT06073834 · LUNG-I3